MINNEAPOLIS, March 1 /PRNewswire/ -- Sunlight Research(TM) - The Source for Patent Analysis (www.sunlightresearch.com) today announced the release of its report analyzing the U.S. human mesenchymal stem cells (MSCs) patent portfolio of Osiris Therapeutics, Inc. (Nasdaq: OSIR).

The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Bone Grafts Market http://www.reportlinker.com/p0119465/World-Bone-Grafts-Market.html This report analyzes the US market for Bone Grafts in Millions of US$.

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C.

Genzyme Corp.